title: Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes.
authors.affiliation: Novartis Pharmaceutical Corporation, One Health Plaza, East Hanover, NJ 07936, USA. james.foley@novartis.com
authors.forename: J E
authors.initials: JE
authors.lastname: Foley
authors.forename: M
authors.initials: M
authors.lastname: Ligueros-Saylan
authors.forename: Y-L
authors.initials: YL
authors.lastname: He
authors.forename: J J
authors.initials: JJ
authors.lastname: Holst
authors.forename: C F
authors.initials: CF
authors.lastname: Deacon
authors.forename: B E
authors.initials: BE
authors.lastname: Dunning
authors.forename: A
authors.initials: A
authors.lastname: Leone-Jones
authors.forename: T
authors.initials: T
authors.lastname: Yu
authors.forename: D E
authors.initials: DE
authors.lastname: Kelley
mesh_terms: D000218:Adamantane / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D000328:Adult; D003922:Diabetes Mellitus, Type 1 / Q000097:blood* / Q000188:drug therapy*; D005247:Feeding Behavior / Q000187:drug effects; D005260:Female; D005749:Gastric Inhibitory Polypeptide / Q000097:blood; D005934:Glucagon / Q000097:blood*; D052216:Glucagon-Like Peptide 1 / Q000097:blood; D006801:Humans; D007003:Hypoglycemia / Q000188:drug therapy; D007004:Hypoglycemic Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D009570:Nitriles / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D011759:Pyrrolidines / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D000077597:Vildagliptin
chemical_list: D007004:Hypoglycemic Agents; D009570:Nitriles; D011759:Pyrrolidines; D005749:Gastric Inhibitory Polypeptide; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; D000077597:Vildagliptin; D000218:Adamantane